Oncology
Refine Search
Biotechnology
Privately-held US biotech Alloy Therapeutics has announced a strategic collaboration and license agreement with Takeda Pharmaceutical. 21 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval of Ziihera (zanidatamab-hrii) 50mg/mL for injection for intravenous use, say the drug’s developer, Jazz Pharmaceuticals. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Biotechnology
Bioplatform company builder Flagship Pioneering has announced its companies Ampersand Biomedicines and Montai Therapeutics have entered into agreements to identify targeted molecules that could potentially be further developed as treatments for obesity and lung cancer. 20 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Biosimilars
Sweden-based Xbrane Biopharma and Intas Pharmaceuticals have announced an exclusive global licensing and co-development agreement for the former company’s Opdivo (nivolumab) biosimilar candidate. 20 November 2024
Biotechnology
A pair of industry veterans have teamed up to create Jupiter Bioventures, a San Francisco-based biotech venture foundry promised to build bold, science-driven therapeutics companies. 20 November 2024
Biotechnology
The UK’s health technology assessor the Institute for Health and Clinical Excellence (NICE) says that talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged. 20 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has granted accelerated approved the supplemental new drug application (sNDA) for Iclusig (ponatinib). 20 March 2024
Biotechnology
Samsung Life Science Fund announced Samsung’s investment in Boston, USA-based BrickBio, a pre-clinical-stage biopharmaceutical company focused on developing precision biologics using an expanded genetic code. 19 March 2024
Pharmaceutical
Shanghai-based KeChow Pharma has secured approval in its home country for tunlametinib, a MEK blocker which was discovered and developed by the firm in-house. 19 March 2024
Pharmaceutical
Shares of Canada-headquartered Fusion Pharmaceuticals were up more than 95% at $20.80 in pre-market activity, on the news of a takeover bid from UK pharma major AstraZeneca. 19 March 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted the resubmission of US critical care specialist Citius Pharmaceuticals’ Biologics License Application (BLA) for Lymphir (denileukin diftitox). 19 March 2024
Biotechnology
UK pharma major GSK (LSE: GSK) updated on the development of its Jemperli (dostarlimab) at the Society of Gynecologic Oncology 2024 Annual Meeting on Women’s Cancer on March 16. 18 March 2024
Biotechnology
Clinical-stage biotech Biotheus has entered into a collaboration with fellow China-based Hansoh Pharmaceutical following their current partnership since 2022. 18 March 2024
Biotechnology
Two meeting of the US Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) held on Friday resulted in recommendations for approval of two cell therapies – Abecma (idecabtagene vicleucel) and Carvykti (ciltacabtagene autoleucel. 16 March 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted accelerated approval for a new indication of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy from US pharma major Bristol Myers Squibb (NYSE: BMY). 16 March 2024
Pharmaceutical
A US Food and Drug Administration (FDA) advisory panel has voted in favor of the clinical benefit/risk profile of imetelstat for transfusion-dependent (TD) anemia in adults with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). 15 March 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has won a fifth approval for Cejemly (sugemalimab) in China. 15 March 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Biotechnology
San Diego-based biotech Endeavor BioMedicines has appointed Enoch Kariuki as president and Vishaal Turakhia as chief financial officer. 14 March 2024
Pharmaceutical
German firms Bayer and Aignostics have announced a strategic collaboration on several artificial intelligence (AI)-powered approaches with applications in precision oncology drug research and development. 14 March 2024
Biotechnology
German antibody drug conjugate (ADC) specialist Tubulis has announced the successful completion of an upsized and oversubscribed 128 million euros ($138.8 million) Series B2 financing. 14 March 2024
Biotechnology
Once dubbed as me-too copycats and fast followers, Chinese biotechs are flocking to innovation mix, or combinatorial innovation, hoping to discover a novel therapy based on a mixture of existing resources, according to the consulting firm Clarivate. 13 March 2024
Generics
In what the company describes as “a significant stride towards making advanced cancer treatment accessible to all,” Indian drugmaker Zydus Lifesciences (NYSE: ZYDUSLIFE) has launched olaparib, a PARP inhibitor marketed by UK pharma major AstraZeneca (LSE: AZN) as Lynparza, under the brand name Ibyra in India. 13 March 2024
Biotechnology
US pharma giant Pfizer today announced further positive data for its recently acquired Adcetris (brentuximab vedotin). 12 March 2024
Biotechnology
US clinical-stage biotech IDRx today announced that it has strengthened its leadership team with the appointments of Tim Clackson, as chief executive and Brad Dahms as chief financial officer and chief business officer. 12 March 2024
Biotechnology
Shanghai-based CARsgen Therapeutics has announced that zevorcabtagene autoleucel (CT053), or zevor-cel, its autologous CAR T-cell developed for multiple myeloma, has been approved by China’s National Medical Products Administration (NMPA). 11 March 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze